Matthew Shawn Morris

Director Matthew Shawn Morris sells 112.8K shares (62.3% reduction) for $3.1M via scheduled 10b5-1 plan

Matthew Shawn Morris, a director at Privia Health (PRVA), executed 2 separate sales totaling 112,759 shares for $3,076,868.49 under a pre-arranged 10b5-1 trading plan on July 2 and July 6, 2026, reducing his non-derivative holdings from 180,947 to 68,188 shares. The blended average price of $27.29 was achieved near the current price of $27.23 and within the 52-week range. Although this represents a 62.3% reduction in his non-derivative stake, Morris retains substantial derivative holdings totaling 6,602,966 shares in the form of stock options, preserving meaningful economic exposure to the company. The scheduled nature of the sales under a 10b5-1 plan precludes timing-based interpretation; these trades reflect a pre-committed execution, not a discretionary signal about near-term company prospects or market conditions.

Director Matthew Shawn Morris sold 135,498 shares for $3.6M via scheduled 10b5-1 plan at avg $26.32, retaining 76,651 non-derivative shares

Director Matthew Shawn Morris executed three separate sales totaling 135,498 shares for $3,566,335.37 on June 30 and July 1, 2026, at prices ranging from $25.72 to $26.93 (blended average $26.32). This represented a -63.9% reduction in his non-derivative holdings, from 212,149 to 76,651 shares. However, this transaction is part of a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled rather than discretionary. Morris retains significant economic exposure through derivative holdings of 6,857,437 stock options across two vehicles, indicating his overall position in PRVA remains substantial despite the common-stock reduction. The stock currently trades at $27.36, near its 52-week high of $27.52 and up 31.5% over 30 days, but the scheduled nature of these sales means they do not reflect a timed market judgment.

Director Matthew Shawn Morris sold 151,322 shares ($3.8M) via scheduled 10b5-1 plan at $25.33, retaining 76,651 non-derivative shares and 7,108,970 in stock options.

Director Matthew Shawn Morris executed 2 separate sales totaling 151,322 shares for $3,832,986.26 on 2026-06-26 and 2026-06-29, pursuant to a pre-arranged 10b5-1 trading plan, meaning the transaction was scheduled rather than discretionary. The sales reduced his non-derivative holdings by -66.4% from 227,973 shares to 76,651 shares; however, his derivative holdings total 7,108,970 shares across two stock option positions, representing a substantially larger economic stake that remains intact. The stock currently trades at $25.73, near its 52-week high of $26.51 with a steep P/E of 151.35 relative to net income of $3.1M on $603.8M quarterly revenue. Since the trade was scheduled under a 10b5-1 plan, it reflects execution of a predetermined arrangement rather than a timing decision by the insider.